Cannabis use by teenagers doubles their risk of developing psychotic and bipolar disorders
Cannabis use by teenagers doubles their risk of developing psychotic and bipolar disorders” style=”width:100%;max-height:420px;object-fit:cover;border-radius:8px;display:block;” />#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
I don’t see a summary provided in your prompt. Please provide the article summary so I can write the clinically relevant sentences explaining why this matters for clinicians and patients.
A large prospective cohort study found that adolescents who use cannabis have approximately double the risk of developing psychotic disorders and bipolar disorder in early adulthood compared to non-users, with risk increasing with frequency and potency of use. The findings suggest a developmental window of vulnerability during the teenage years when the brain is still undergoing maturation, particularly in regions involved in emotional regulation and psychosis risk. This research strengthens the evidence that cannabis exposure during adolescence carries substantial psychiatric risks distinct from adult use, highlighting the need for clinicians to screen teenagers for cannabis use during routine care. For patients with personal or family histories of psychotic or bipolar disorders, cannabis avoidance during adolescence appears particularly important given the compounded genetic vulnerability. Clinicians should counsel adolescent patients and their families about these specific psychiatric risks when discussing substance use prevention and early intervention strategies.
“What we’re seeing in the data is clear: adolescent cannabis use, particularly with today’s high-potency products, carries a real neurobiological risk during a critical window of brain development, and I counsel families accordingly, but we also need to acknowledge that correlation isn’t causation and that many factors contribute to psychotic illness. My job is to help patients and parents understand the actual risk in context so they can make informed decisions, not to shame or oversimplify.”
🧠 Adolescent cannabis use represents a significant psychiatric risk factor that warrants clinical attention, particularly given that regular use may double the risk of psychotic and bipolar spectrum disorders during a critical neurodevelopmental window. However, clinicians should recognize that this association does not establish causation, and important confounders such as genetic predisposition, concurrent substance use, socioeconomic stressors, and untreated primary psychiatric conditions may partially explain the observed relationship. The potency of modern cannabis products, frequency and age of initiation, and individual vulnerability factors (including family history) likely modify risk substantially, meaning that not all adolescent users will develop serious mental illness. Additionally, the directionality of causation remains incompletely understood, as emerging psychotic or bipolar symptoms may drive cannabis use as self-medication rather than the reverse. Clinicians should incorporate direct, non-judgmental screening for cannabis use during adolescent visits, educ
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
